RVMD
Revolution Medicines, Inc.
Stock
$205.26+0.78 (+0.38%)Close Sep 30, 2026
Income statement
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $12M | $35M | $29M | $43M | $50M | $20M |
| R&D | $987M | $592M | $423M | $253M | $187M | $132M | $92M | $51M |
| Operating income | −$1.2B | −$690M | −$487M | −$258M | −$188M | −$111M | −$54M | −$40M |
| Non-operating income | $51M | $89M | $47M | $9.2M | $917K | $2.2M | $2.1M | −$1.5M |
| Pretax income | −$1.1B | −$601M | −$440M | −$249M | −$187M | −$109M | −$52M | −$42M |
| Taxes | $0 | −$753K | −$3.5M | −$420K | $0 | −$371K | −$4.4M | $0 |
| Net income | −$1.1B | −$600M | −$436M | −$249M | −$187M | −$108M | −$48M | −$42M |
| Diluted EPS | −$5.95 | −$3.58 | −$3.86 | −$3.08 | −$2.57 | −$2.01 | −$22.33 | −$21.24 |
| Diluted shares | 190.1M | 167.7M | 113.1M | 80.6M | 72.8M | 54.9M | 2.8M | 2.3M |
| Revenue growth | — | −100.0% | −67.3% | +20.4% | −31.6% | −14.1% | +148.2% | — |
| Operating margin | — | — | −4,207.1% | −730.0% | −639.7% | −257.5% | −108.2% | −200.0% |
| Net margin | — | — | −3,768.3% | −703.0% | −636.6% | −251.6% | −95.2% | −207.2% |
Cost of revenue, other operating expenses, non-operating income and taxes are the differences between the lines reported around them.